Alterations of the spindle checkpoint pathway in clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas

International Journal of Cancer

Volumn 137, Issue 11, 2015, Pages 2589-2606

  Arai, Eri ^a   Gotoh, Masahiro ^a   Tian, Ying ^a   Sakamoto, Hiromi ^a   Ono, Masaya ^a   Matsuda, Akio ^b   Takahashi, Yoriko ^c   Miyata, Sayaka ^c   Totsuka, Hirohiko ^d   Chiku, Suenori ^e   Komiyama, Motokiyo ^f   Fujimoto, Hiroyuki ^f   Matsumoto, Kenji ^b   Yamada, Tesshi ^a   Yoshida, Teruhiko ^a   Kanai, Yae ^a  

^a NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

^b NATIONAL RESEARCH INSTITUTE FOR CHILD HEALTH AND DEVELOPMENT   (Japan)

^c Mitsui Knowledge Industry Co   (Japan)

^d HITACHI LTD   (Japan)

^e MIZUHO INFORMATION AND RESEARCH INSTITUTE   (Japan)

^f NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

aurora kinases; clear cell renal cell carcinoma (RCC); CpG island methylator phenotype (CIMP); multi layer omics analysis; spindle checkpoint

Indexed keywords

AURORA A KINASE; AURORA B KINASE; CELL CYCLE PROTEIN 20; TRANSCRIPTOME; AURORA KINASE; MICROTUBULE ASSOCIATED PROTEIN; PROTEOME;

ARTICLE; AURKA GENE; AURKB GENE; BIRC5 GENE; BUB1 GENE; CARCINOGENESIS; CDC20 GENE; CELL CYCLE CHECKPOINT; CELL CYCLE REGULATION; CELL STRUCTURE; CHROMOSOME SEPARATION; CHROMOSOMES AND CHROMOSOMAL PHENOMENA; CONTROLLED STUDY; CPG ISLAND; CPG ISLAND METHYLATOR PHENOTYPE; DNAH10 GENE; DNAH2 GENE; DNAH5 GENE; FEMALE; GENE; GENE DELETION; GENE DOSAGE; GENE INSERTION; GENE OVEREXPRESSION; GENETIC DISORDER; HAUS8 GENE; HUMAN; HUMAN TISSUE; KIDNEY CARCINOMA; KIDNEY CORTEX; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; METAPHASE; NEK2 GENE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RP1 GENE; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SPC25 GENE; SPINDLE CELL; AGED; CHROMOSOME ABERRATION; DNA METHYLATION; GENETICS; KIDNEY TUMOR; M PHASE CELL CYCLE CHECKPOINT; MIDDLE AGED; PATHOLOGY;

AGED; AURORA KINASES; CARCINOGENESIS; CARCINOMA, RENAL CELL; CHROMOSOME ABERRATIONS; CPG ISLANDS; DNA METHYLATION; FEMALE; GENE DOSAGE; HUMANS; KIDNEY NEOPLASMS; M PHASE CELL CYCLE CHECKPOINTS; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MIDDLE AGED; PHENOTYPE; PROTEOME; TRANSCRIPTOME;

EID: 84941739822     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29630     Document Type: Article

References (50)

1. You JS, Jones PA., Cancer genetics and epigenetics: two sides of the same coin? Cancer Cell 2012; 22: 9-20.
2. Baylin SB, Jones PA., A decade of exploring the cancer epigenome-biological and translational implications. Nat Rev Cancer 2011; 11: 726-34.
3. Kanai Y., Genome-wide DNA methylation profiles in precancerous conditions and cancers. Cancer Sci 2010; 101: 36-45.
4. Arai E, Kanai Y., DNA methylation profiles in precancerous tissue and cancers: carcinogenetic risk estimation and prognostication based on DNA methylation status. Epigenomics 2010; 2: 467-81.
5. Issa JP., CpG island methylator phenotype in cancer. Nat Rev Cancer 2004; 4: 988-93.
6. Shen L, Toyota M, Kondo Y, et al., Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc Natl Acad Sci USA 2007; 104: 18654-9.
7. Toyota M, Ahuja N, Suzuki H, et al., Aberrant methylation in gastric cancer associated with the CpG island methylator phenotype. Cancer Res 1999; 59: 5438-42.
8. Ljungberg B, Campbell SC, Choi HY, et al., The epidemiology of renal cell carcinoma. Eur Urol 2011; 60: 615-21.
9. Arai E, Kanai Y, Ushijima S, et al., Regional DNA hypermethylation and DNA methyltransferase (DNMT) 1 protein overexpression in both renal tumors and corresponding nontumorous renal tissues. Int J Cancer 2006; 119: 288-96.
10. Arai E, Ushijima S, Fujimoto H, et al., Genome-wide DNA methylation profiles in both precancerous conditions and clear cell renal cell carcinomas are correlated with malignant potential and patient outcome. Carcinogenesis 2009; 30: 214-21.
11. Morris MR, Maher ER., Epigenetics of renal cell carcinoma: the path towards new diagnostics and therapeutics. Genome Med 2010; 2: 59.
12. Bibikova M, Le J, Barnes B, et al., Genome-wide DNA methylation profiling using Infinium® assay. Epigenomics 2009; 1: 177-200.
13. Arai E, Chiku S, Mori T, et al., Single-CpG-resolution methylome analysis identifies clinicopathologically aggressive CpG island methylator phenotype clear cell renal cell carcinomas. Carcinogenesis 2012; 33: 1487-93.
14. Sato Y, Yoshizato T, Shiraishi Y, et al., Integrated molecular analysis of clear-cell renal cell carcinoma. Nat Genet 2013; 45: 860-7.
15. Eble JN, Togashi K, Pisani P., Renal cell carcinoma. In:, Eble JN, Sauter G, Epstein JI, et al., eds. World Health Organization classification of tumours. Pathology and genetics. Tumours of the urinary system and male genital organs. Lyon: IARC Press, 2004. 10-43.
16. Fuhrman SA, Lasky LC, Limas C., Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol 1982; 6: 655-63.
17. Sobin LH, Gospodarowicz MK, Wittekind C, eds. International Union Against Cancer. TNM classification of malignant tumors, 7th ed. New York: Wiley, 2009.
18. Tian Y, Arai E, Gotoh M, et al., Prognostication of patients with clear cell renal cell carcinomas based on quantification of DNA methylation levels of CpG island methylator phenotype marker genes. BMC Cancer 2014; 14: 772.
19. Arai E, Sakamoto H, Ichikawa H, et al., Multilayer-omics analysis of renal cell carcinoma, including the whole exome, methylome and transcriptome. Int J Cancer 2014; 135: 1330-42.
20. Wang L, Tsutsumi S, Kawaguchi T, et al., Whole-exome sequencing of human pancreatic cancers and characterization of genomic instability caused by MLH1 haploinsufficiency and complete deficiency. Genome Res 2012; 22: 208-19.
21. Ng PC, Henikoff S., Accounting for human polymorphisms predicted to affect protein function. Genome Res 2002; 12: 436-46.
22. Hicks S, Wheeler DA, Plon SE, et al., Prediction of missense mutation functionality depends on both the algorithm and sequence alignment employed. Hum Mutat 2011; 32: 661-8.
23. Sim NL, Kumar P, Hu J, et al., SIFT web server: predicting effects of amino acid substitutions on proteins. Nucleic Acids Res 2012; 40: W452-7.
24. Van Loo P, Nordgard SH, Lingjærde OC, et al., Allele-specific copy number analysis of tumors. Proc Natl Acad Sci USA 2010; 107: 16910 -1 5.
25. Li A, Liu Z, Lezon-Geyda K, et al., GPHMM: an integrated hidden Markov model for identification of copy number alteration and loss of heterozygosity in complex tumor samples using whole genome SNP arrays. Nucleic Acids Res 2011; 39: 4928-41.
26. Ono M, Shitashige M, Honda K, et al., Label-free quantitative proteomics using large peptide data sets generated by nanoflow liquid chromatography and mass spectrometry. Mol Cell Proteomics 2006; 5: 1338-47.
27. Masuda T, Tomita M, Ishihama Y., Phase transfer surfactant-aided trypsin digestion for membrane proteome analysis. J Proteome Res 2008; 7: 731-40.
28. Harrington EA, Bebbington D, Moore J, et al., VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo. Nat Med 2004; 10: 262-7.
29. Cancer Genome Atlas Research Network. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature 2013; 499: 43-9.
30. Varela I, Tarpey P, Raine K, et al., Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature 2011; 469: 539-42.
31. Chapelin C, Duriez B, Magnino F, et al., Isolation of several human axonemal dynein heavy chain genes: genomic structure of the catalytic site, phylogenetic analysis and chromosomal assignment. FEBS Lett 1997; 412: 325-30.
32. Bu W, Su LK., Regulation of microtubule assembly by human EB1 family proteins. Oncogene 2001; 20: 3185-92.
33. Tsai CY, Ngo B, Tapadia A, et al., Aurora-A phosphorylates Augmin complex component Hice1 protein at an N-terminal serine/threonine cluster to modulate its microtubule binding activity during spindle assembly. J Biol Chem 2011; 286: 30097-106.
34. Wu G, Lin YT, Wei R, et al., Hice1, a novel microtubule-associated protein required for maintenance of spindle integrity and chromosomal stability in human cells. Mol Cell Biol 2008; 28: 3652-62.
35. Dalgliesh GL, Furge K, Greenman C, et al., Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. Nature 2010; 463: 360-3.
36. Beall SA, Boekelheide K, Johnson KJ., Hybrid GPCR/cadherin (Celsr) proteins in rat testis are expressed with cell type specificity and exhibit differential Sertoli cell-germ cell adhesion activity. J Androl 2005; 26: 529-38.
37. Menke A, Giehl K., Regulation of adherens junctions by Rho GTPases and p120-catenin. Arch Biochem Biophys 2012; 524: 48-55.
38. Kwon OH, Park JL, Kim M, et al., Aberrant up-regulation of LAMB3 and LAMC2 by promoter demethylation in gastric cancer. Biochem Biophys Res Commun 2011; 406: 539-45.
39. Tsukita S, Yamazaki Y, Katsuno T, et al., Tight junction-based epithelial microenvironment and cell proliferation. Oncogene 2008; 27: 6930-8.
40. Guo G, Gui Y, Gao S, et al., Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma. Nat Genet 2012; 44: 17 -1 9.
41. Cremona CA, Behrens A., ATM signalling and cancer. Oncogene 2014; 33: 3351-60.
42. Nikonova AS, Astsaturov I, Serebriiskii IG, et al., Aurora A kinase (AURKA) in normal and pathological cell division. Cell Mol Life Sci 2013; 70: 661-87.
43. Poon RY., Aurora B: hooking up with cyclin-dependent kinases. Cell Cycle 2013; 12: 1019-20.
44. Khan J, Ezan F, Crémet JY, et al., Overexpression of active Aurora-C kinase results in cell transformation and tumour formation. PLoS One 2011; 6: e26512.
45. Li F, Ambrosini G, Chu EY, et al., Control of apoptosis and mitotic spindle checkpoint by survivin. Nature 1998; 396: 580-4.
46. Ricke RM, van Deursen JM., Aurora B hyperactivation by Bub1 overexpression promotes chromosome missegregation. Cell Cycle 2011; 10: 3645-51.
47. van Zon W, Wolthuis RM., Cyclin A and Nek2A: APC/C-Cdc20 substrates invisible to the mitotic spindle checkpoint. Biochem Soc Trans 2010; 38: 72-7.
48. Wei RR, Sorger PK, Harrison SC., Molecular organization of the Ndc80 complex, an essential kinetochore component. Proc Natl Acad Sci USA 2005; 102: 5363-7.
49. Armakolas A, Klar AJ., Left-right dynein motor implicated in selective chromatid segregation in mouse cells. Science 2007; 315: 100-1.
50. Cheung CH, Coumar MS, Chang JY, et al., Aurora kinase inhibitor patents and agents in clinical testing: an update (2009-10). Expert Opin Ther Pat 2011; 21: 857-84.